Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinaverium Bromide for Post-ESWL Pancreatitis Prevention
NCT06936800Enrolling by invitation
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chronic pancreatitis (CP) comparing Pinaverium Bromide with Placebo (2 arms). Primary endpoint: Incidence and grading of pancreatitis after P-ESWL. Started Mar 2025; status: enrolling by invitation.
02
Drugs
pinaverium
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT06936800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936800.